VNVelu Nair

Velu Nair

*This is an algorithmically generated author record based on publicly available information.

Velu Nair has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Decoding thrombosis at high altitude: A comprehensive scoping review

    by Uday Yanamandra, Celine Raphael, Roopika Peela, Vivek Aggarwal, Velu Nair

  • KMT2A amplification: rare cytogenetic abnormality in a case of pediatric acute lymphoblastic leukemia

    by Dhara Shah, Velu Nair, Chaitrangi Rohekar, Vijaykumar Shirure, Sandipkumar Kheni, Neha Motwani, Grishma Sukhwal, Raj Gabani, Yoshaan Joshi

    Background: Rearrangements or translocations involving the KMT2A gene are well-recognized genetic abnormalities in acute lymphoblastic leukemia (ALL) across both adult and pediatric populations, and their presence is typically associated with adverse prognosis and high-risk disease. In contrast, KMT2A gene amplification is an exceedingly rare abnormality in ALL, with only a few reported cases till date, predominantly in adults. Owing to its extreme rarity, the prognostic significance of KMT2A amplification in pediatric ALL remains unclear, although available reports in adult cases suggest an association with poor outcomes. Case Presentation: This is a case of KMT2A amplification in a 4-year-old child diagnosed with B-cell ALL who presented with standard-risk disease features and achieved complete remission following induction chemotherapy, maintaining remission at 12 months post-diagnosis. Similar findings from limited Western literature also suggest that KMT2A amplification does not adversely affect clinical outcomes in pediatric cases. To the best of our knowledge, this is the first reported case of this rare genetic abnormality in pediatric ALL from India. Conclusion: This case highlights a rare cytogenetic abnormality—KMT2A amplification—in pediatric ALL, which, despite being an adverse prognostic factor in adult acute leukemia, did not appear to negatively impact clinical outcome in the pediatric age group.

  • Feasibility and efficacy of partial replacement of post transplantation cyclophosphamide with bendamustine on day +4 for graft versus host disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation

    by Velu Nair, Manthan Kathrotiya, Vijaykumar Shirure, Shruti Bhise, Sandip Kheni, Jayani Patel, Neha Motwani, Dhara Shah, Grishma Sukhwal, Chaitrangi Paranjape, et al.

    PT-CY use in T cell-replete haploidentical HCT has significantly improved outcomes. However, hyperhydration with MESNA in CY administration poses a challenge, in patients with cardiac/ renal problems. PT-CY also increases VOD risk with prior exposure to hepatotoxic drugs. Katsanis et al. in a phase Ia trial in patients undergoing HCT for hematological malignancies showed that partially replacing PT-CY with PT-BEN had comparable outcomes to conventional PT-CY. We conducted an ambispective study in 54 patients [haplo (39), MSD(14), and MUD(1)] with nonmalignant hematological disorders and hematological malignancies in pediatric and adult patients undergoing HCT (MAC/RIC) from February 2019 to May 2024. GvHD prophylaxis comprised of PT-CY/BEN (PT-CY 50 mg/kg Day +3; PT-BEN 90 mg/m2 Day +4) in a prospective arm (n = 21) and PT-CY/CY (50 mg/kg on Days +3, +4; comparator arm) in ambispective (prospective 12; retrospective 21) arm. In both groups, immunosuppression with CNI and MMF was also given. PT-CY/BEN was comparable to PT-CY/CY in terms of safety, efficacy, and GVHD prevention. In the PT-CY/BEN group, there was earlier neutrophil (0.008) and platelet (0.0057) engraftment with significantly lower BK viremia. Incidence of bacterial infection, TRM, EFS, and OS were comparable in both groups.


  • Open Access

    Epidemiology and pathophysiology of vascular thrombosis in acclimatized lowlanders at high altitude: A prospective longitudinal study

    by Velu Nair, Surinderpal Singh, Mohammad Zahid Ashraf, Uday Yanamandra, Vivek Sharma, Amit Prabhakar, Rehan Ahmad, Tathagata Chatterjee, Vineet Behera, Vivek Guleria, et al.


  • Collaborations, colleagues, and friendships: The Hematology Branch and blood disease centers in Asia

    by Adrian Wiestner, Surapol Issaragrisil, David W. Kaufman, Keiya Ozawa, Shinji Nakao, Sachiko Kajigaya, Jianxiang Wang, Zhijie Wu, Vo Thi Thanh Binh, Rishi Dhawan, et al.

  • Open Access

    Radiographical Spectrum of High-altitude Pulmonary Edema: A Pictorial Essay

    by Velu Nair, Uday Yanamandra, Amul Gupta, Rajan Grewal, Vasu Vardhan, Puneet Saxena, Deepak Mulajkar

    Background: High altitude pulmonary edema (HAPE) is a common cause of hospitalization in high altitude areas with significant morbidity. The clinical presentation of HAPE can overlap with a broad spectrum of cardiopulmonary diseases. Also, it is associated with varied radiological manifestations mimicking other conditions and often leading to unnecessary and inappropriate treatment. Patients and methods: The primary aim of the study was to study the various radiological manifestations of HAPE through real-world chest radiographs. We present six different chest X-ray patterns of HAPE as a pictorial assay, at initial presentation, and after the resolution of symptoms with supplemental oxygen therapy and bed rest alone. Results: HAPE can present as bilateral symmetrical perihilar opacities, bilateral symmetrical diffuse opacities, unilateral diffuse opacities, bilateral asymmetrical focal opacities, and even lobar consolidation with lower zone or less commonly upper zonal predilection. These presentations can mimic many common conditions like heart failure, acute respiratory distress syndrome, pulmonary embolism, aspiration pneumonitis, pneumonia, malignancy, and tuberculosis. Conclusion: A holistic clinical-radiological correlation coupled with analysis of the temporal course can help high-altitude physicians in differentiating true HAPE from its mimics.


  • Open Access

    Single Dose Preemptive Plerixafor for Stem Cell Mobilization for ASCT After Lenalidomide Based Therapy in Multiple Myeloma: Impact in Resource Limited Setting

    by Rajiv Kumar, Rajan Kapoor, Bhushan Asthana, Jasjit Singh, Tarun Verma, Rajesh Chilaka, N. K. Singh, Ajay Sharma, S. Das, Velu Nair

    Peripheral blood stem cell mobilization with cytokines for autologous stem cell transplant in multiple myeloma is adversely affected by initial induction therapy consisting of either Lenalidomide or cytotoxic drugs, with failure rates of up to 45%. The use of Plerixafor with G-CSF for PBSC mobilisation significantly improves the chances of a successful mobilization. Plerixafor is a costly therapy and increases the overall costs of ASCT which can affect the number of patients being taken up for ASCT in resource limited settings. We prospectively studied the impact of single dose preemptive Plerixafor for PBSC mobilization in patients with prior Lenalidomide exposure. 26 patients who had received Lenalidomide based induction protocol underwent PBSC mobilisation during the study period with G-CSF 10 μg/kg/day SC for 4 days and single dose preemptive Plerixafor 240 μg/kg SC stat 11 h before the scheduled PB stem cell harvest on D5, based on a D4 PB CD34+ counts of <20/μL. A median of 07 cycles of Lenalidomide based combination therapy was used for induction therapy prior to ASCT. 84% patients underwent successful mobilization with one sitting of stem cell harvest post a single dose of Inj Plerixafor. 7.6% patients failed to mobilise the predefined minimum cell dose of CD34 and could not be taken up for ASCT. The median CD34% of the harvest bag sample was 0.33% (0.1–0.97%). Injection site erythema (34%), paresthesia’s (34%) and nausea (30%) were the commonest adverse events reported post Inj Plerixafor. We did a real-world cost analysis for a resource limited setting for PBSC mobilization and found significant cost savings for the preemptive Plerixafor group.


  • Open Access

    Monitoring of response to therapy with imatinib mesylate in Chronic Myeloid Leukemia in chronic phase (CML-CP)

    by Velu Nair, Ajay Sharma, Jyoti Kotwal, M. Bhikshapathy, D.K. Mishra, Satyaranjan Das, Sanjeevan Sharma, Rajan Kapoor, Jasjit Singh, Vivek Nair, et al.


  • Open Access

    A Fludarabine Based Conditioning Regimen Associated with A Good Survival Following HLA Identical Sibling/Family Donor Transplants in Patients with Aplastic Anemia.

    by Mammen Chandy, Biju George, Vikram Mathews, Shashikant Apte, Velu Nair, Uday Deotare, Rajasekhar Thiurgnanam, Anjali Jaydeep Kelkar, Samir Melinkeri, Satyaranjan Das, et al.

    Abstract 1194 Poster Board I-216 Between January 2001 and June 2009, 120 patients with aplastic anemia underwent HLA identical sibling or family donor transplants using a combination of Fludarabine 150-180 mg/m2 over 5 days and Cyclophosphamide 120 mg/kg over 2 days as the conditioning regimen. Antithymocyte globulin (ATG) 10 mg/kg x 4 days in addition was used in 34 patients. Graft versus host disease (GVHD) prophylaxis consisted of Cyclosporine with low dose Methotrexate. Graft source included peripheral blood stem cells (PBSC) in 108 and G-CSF stimulated bone marrow in 12. Seventy patients (58.3%) were considered as high risk (presence of fever/infection at time of HSCT or >20 transfusions prior to HSCT or failed previous immunosuppressive therapy). There were 79 males and 41 females with a median age of 22 years (range: 2 - 51) including 36 children (age 0.5 × 109/L) was 12 days (range: 7-19) while platelet engraftment (Platelet count > 20 × 109/L) occurred at a median of 13 days (range: 0 -30). Acute GVHD occurred in 38 patients (33.3%) with grade III-IV GVHD in 13.1%. Acute GVHD was not significantly lower in patients where ATG was used in conditioning (21.8% with ATG vs 38.2% without ATG; p = 0.129). Nine patients (7.5%) had veno-occlusive disease of the liver while 11 (9.1%) had hemorrhagic cystitis; all responded well to supportive therapy. Bacterial infections were documented in 28% of transplant recipients while fungal infections (both probable and definite) occurred in 23%. CMV reactivation was seen in <5%. Chronic GVHD occurred in 32.6% of evaluable transplant recipients and was limited in a majority of patients. At a median follow up of 30 months (range: 1 – 105), 88 patients (73.3%) are alive and well. Causes of death included sepsis in 19, acute GVHD in 7, chronic GVHD in 4, primary graft failure in 1 and road traffic accident in 1 patient. The overall survival was similar among children (75%) and adults (72.6%). The overall survival was significantly lower in the high risk group (60%) compared to the low risk group (92%; p = 0.0001).


  • Open Access

    Spectrum of Haemoglobinopathies in a Tertiary Care Hospital of Armed Forces

    by Gs Chopra, V Nair, Pk Gupta, Dk Mishra, A Sharma, Op Mathew